Taiwan FDA has granted clearance for Senhwa Biosciences’ investigational new drug (IND) application to initiate a Phase II clinical trial of Silmitasertib(CX-4945) to treat hospitalised patients with moderate to severe Covid-19.
Senhwa plans to initiate patient enrolment, upon receiving approval from the IRB.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this Phase II proof of concept trial, Senhwa aims to demonstrate Silmitasertib as a therapeutic strategy that would not be restricted to just one specific viral infection, but applicable to several viruses.
Silmitasertib inhibits CK2 protein kinase which implicates regulation of several signaling pathways that are important for innate immune responses.
CK2 inhibitors dampen NF-κB activation in macrophages and consequent IL-1, IL-6 and IL-10 cytokine secretion by these cells.
CK2 inhibition further boosts type I IFN production in macrophages in viral infection settings.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe approach of Silmitasertib targeting host cell CK2 protein against the SARS-CoV-2 variants is also expected to be clinically effective against other viruses including influenza and Respiratory Syncytical Virus (RSV).
Silmitasertib also showed clinical benefits by expediting the recovery speed in patients with either mild, moderate or severe symptoms of Covid-19 in two investigator-initiated trials (IIT) in the US.
Covid-19 infections might also increase the risk of death in populations with cancer, immunodeficiency, or chronic illness histories.
